Advances in chemoprevention of head and neck cancer
Advances in chemoprevention of head and neck cancer
复制标题
DOI：
10.1634/theoncologist.9-3-302
复制
发表时间：
2004-01-01
期刊：
影响因子：
5.8
通讯作者：
Shin, DM
中科院分区：
文献类型：
--
作者：
Rhee, JC;Khuri, FR;Shin, DM
头颈部鳞状细胞癌是一种晚期预后不良的毁灭性疾病，约占所有恶性肿瘤的3%，在美国每年估计有37，200例新发病例和11，000例死亡。化学预防是一种有吸引力的策略，其成功已在乳腺癌和家族性腺瘤性息肉病中得到证实。高剂量维甲酸已被证明对口腔癌前病变和预防头颈部第二原发性肿瘤有效。新靶点包括表皮生长因子受体、环氧合酶-2和其他分子靶点。未来头颈癌化学预防研究的挑战包括使用类维生素A和/或新药物实现持久疗效，以及确定最佳剂量和治疗持续时间，同时保持可接受的毒性。
Head and neck squamous cell carcinoma is a devastating disease with a poor outcome in advanced stages, accounting for approximately 3% of all malignancies, with an estimated 37,200 new cases and 11,000 deaths annually in the U.S. Second primary tumors are estimated to occur at an annual rate of 3%-10% and are significant threats to long-term survivors. Chemoprevention is an appealing strategy, and its success has been demonstrated in breast cancer and familial adenomatous polyposis. High-dose retinoids have been shown to be active against oral premalignant lesions and in prevention of second primary tumors in the head and neck. New targets include the epidermal growth factor receptor, cyclooxygenase-2, and other molecular targets. Challenges in future head and neck cancer chemoprevention investigations include achieving long-lasting efficacy with retinoids and/or new agents, and determining the optimal dose and duration of therapy while maintaining acceptable toxicities.